Immunic (NASDAQ: IMUX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.800 | -0.740 | 0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Immunic (NASDAQ: IMUX) through any online brokerage.
Other companies in Immunic’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Adverum Biotechnologies (NASDAQ:ADVM), Celcuity (NASDAQ:CELC), TCR2 Therapeutics (NASDAQ:TCRR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Immunic (NASDAQ: IMUX) was reported by SVB Leerink on Friday, June 3, 2022. The analyst firm set a price target for 9.00 expecting IMUX to rise to within 12 months (a possible 162.39% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Immunic (NASDAQ: IMUX) is $3.43 last updated Today at June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Immunic.
Immunic’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for Immunic.
Immunic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.